Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Medtronic Deep Brain Stimulator Cited by FDA for Flaws

May 2 (Bloomberg) -- A Medtronic Inc. device used to stimulate the brain to treat Parkinson’s disease and other neurological conditions has a potentially life-threatening flaw that triggered the highest-level warning from U.S. regulators.

The wires on the ends of Medtronic’s deep brain stimulators can be damaged by a cap designed to protect the delicate electronics while they are being inserted, the Minneapolis-based company said today in a statement. The wires, known as leads, can be harmed when the connections inside the cap are twisted during surgery or when the cap is removed.

The U.S. Food and Drug Administration classified the issue as a Class 1 recall, meaning there is a reasonable probability that the defect could cause serious health consequences or death. Medtronic alerted physicians to the problem in February and has changed the manufacturing in an effort to fix the issue. The change is under FDA review.

The wires may need to be replaced for the patient to get proper treatment if there is extensive damage, the company said. The caps aren’t used in all surgeries to implant the deep brain stimulators and they don’t always cause harm. If the patients receive therapy as expected after the device is implanted, they aren’t likely to be affected by the flaw, the company said.

Deep brain stimulation uses electrical pulses to treat Parkinson’s disease, tremors, obsessive-compulsive disorder and painful, involuntary muscle contractions known as dystonia. It is also used outside of the U.S. for hard-to-treat epilepsy.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.